Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
暂无分享,去创建一个
M. Kris | C. Azzoli | W. Pao | Gregory Riely | V. Miller | M. Ginsberg | N. Rizvi | Y. Janjigian | M. Pietanza | L. Krug | L. Pereira
[1] J. Neal,et al. Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] J. Shih,et al. Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer. , 2010, Clinical lung cancer.
[3] A. Gemma,et al. F1000 highlights , 2010 .
[4] P. Jänne,et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. , 2010 .
[5] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[6] M. Kris,et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[8] William Pao,et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. , 2009, The Journal of clinical investigation.
[9] S. Ramalingam,et al. Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.
[11] D. Hicklin,et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non–small cell lung cancers , 2007, Molecular Cancer Therapeutics.
[12] William Pao,et al. Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus , 2007, Clinical Cancer Research.
[13] P. Pfeiffer,et al. Simplification of cetuximab (Cet) administration: double dose every second week as a 60 minute infusion , 2007 .
[14] D. Hicklin,et al. Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor , 2007, Clinical Cancer Research.
[15] M. Nakamoto,et al. Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines , 2007, Clinical Cancer Research.
[16] P. Jänne,et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] William Pao,et al. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors , 2006, Clinical Cancer Research.
[18] A. Rossi,et al. Cetuximab in advanced non-small cell lung cancer. , 2006, Critical reviews in oncology/hematology.
[19] M. Maemondo,et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. Paz-Ares,et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Y. Tomizawa,et al. Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Gladish,et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] K. Hagiwara,et al. Phase II study of gefitinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNA-LNA PCR clamp. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Crawford,et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Tolcher,et al. Multi-targeted inhibition of the epidermal growth factor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: A phase I study of cetuximab (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Baselga,et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] P. Jänne,et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.
[28] P. Jänne,et al. Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations , 2005 .
[29] D. Louis,et al. Pulmonary adenocarcinomas with mutant epidermal growth factor receptors. , 2005, The New England journal of medicine.
[30] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[31] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[32] Michael Peyton,et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.
[33] J. Baselga,et al. Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) , 2004, Clinical Cancer Research.
[34] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[35] Prakash Chinnaiyan,et al. Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR) , 2004, Cancer Research.
[36] A. D. Van den Abbeele,et al. Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[38] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[39] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[40] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[41] D W SMITHERS,et al. Clinical Cancer Research , 1941, Lancet.
[42] R. Weichselbaum,et al. Predictors of competing mortality in advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] P. Jänne,et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. , 2005, Journal of the National Cancer Institute.